Breaking Finance News

A statement released earlier today by Guggenheim about Tactile Systems (NASDAQ:TCMD) ups the target price to $47.00

In a report issued 10/12/2017 Guggenheim increased the stock price target of Tactile Systems (NASDAQ:TCMD) to $47.00 stating a potential upside of 0.52%.

Boasting a price of $30.99, Tactile Systems (NASDAQ:TCMD) traded 2.03% higher on the day. With the last stock price close up 16.88% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Tactile Systems has recorded a 50-day average of $32.85 and a two hundred day average of $27.05. Volume of trade was down over the average, with 34,557 shares of TCMD changing hands under the typical 234,268

Performance Chart

Tactile Systems (NASDAQ:TCMD)

With a total market value of $0, Tactile Systems has price-earnings ratio of 119.77 with a one year low of $14.37 and a one year high of $37.88 .

Brief Synopsis About Tactile Systems (NASDAQ:TCMD)

Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. The Company is a manufacturer and distributor of the Flexitouch and Entre Systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch System, a medical device used to treat venous leg ulcers and chronic venous insufficiency. Its products deliver long-term treatment of chronic diseases. The Company provides its products for use in the home and sells them through vascular, wound and lymphedema clinics throughout the United States. The Company offers a platform to deliver at-home healthcare solutions throughout the United States. Its initial area of therapeutic focus is vascular disease, with a focus on advancing the care in treating lymphedema and chronic venous insufficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *